[ skip to content ]

More Information about this image

Aerial shot of campus showing Kaufman Mall, Webb Center and the quad in the background

Bioelectrics Seminar Series - Protective action of Hsp90 inhibitors

Frank Reidy Research Center for Bioelectrics Seminar Series

Speaker: Nektarios Barabutis, M.Sc. Ph.D

Research Scientist

Frank Reidy Research Center for Bioelectrics

Title:Protective action of Hsp90 inhibitors in the LPS Induced Vascular Permeability

When: 9:00 AM, Tuesday, November 8, 2016

Where: 1st floor conference room, IRP II

Abstract: A plethora of Hsp90 inhibitors have been developed to suppress malignancies via the “corruption” of multifarious intracellular cascades which are associated with cancer initiation and progression. An emerging body of evidence suggests that those compounds appear to be promising candidates in the race for the development of novel anti - inflammatory agents. The current presentation will “immerse” on the mechanisms which mediate the beneficial action of those inhibitors against the toxin - induced increase in vascular permeability, a prominent hallmark of vascular inflammation.  Therefore, it will be shown that this particular class of compounds can strongly counteract the LPS induced disruption of vascular integrity by suppressing the pro inflammatory - actions of Hsp90; and by recruiting P53, the so called “guardian of the genome”.

Biosketch: Dr. Barabutis is interested on the exploration of the intracellular mechanisms which are involved in human pathophysiology.  After the completion of his first post - doc training in the Miami Miller School of Medicine (University of Miami) he joined Dr. Catravas’ group in the Vascular Biology Center (Medical College of Georgia). His research elucidates the mechanisms involved in the mediation of the anti - inflammatory activities of Hsp90 inhibitors in the vasculature. He is a research scientist at the ODURF (2014-Present).

            Among other findings, he introduced the anti-oxidative activity of Growth Hormone Releasing Hormone Antagonists in cancers (USA patent: US20100152114 A1USA) and the protective activity of P53 in the LPS induced vascular dysfunction. His work has so far has resulted in 9 first authored and 12 co - authored original research contributions in International peer reviewed journals. He was invited to contribute 2 first authored reviews, 2 editorials and 1 book chapter in the scientific press. He is currently serving as a reviewer for 34 journals and has the pleasure to participate in the editorial board of 11 journals.


Posted By: Barbara Carroll
Date: Mon Nov 07 09:59:54 EST 2016

Site Navigation

Experience Guaranteed

Enhance your college career by gaining relevant experience with the skills and knowledge needed for your future career. Discover our experiential learning opportunities.

Academic Days

Picture yourself in the classroom, speak with professors in your major, and meet current students.

Upcoming Events

From sports games to concerts and lectures, join the ODU community at a variety of campus events.